Biofrontera (NASDAQ:BFRI) Stock Rating Lowered by Wall Street Zen

Biofrontera (NASDAQ:BFRI – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

Several other analysts have also commented on the stock. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Weiss Ratings raised Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Get Biofrontera alerts:

Get Our Latest Stock Report on BFRI

Biofrontera Price Performance

Shares of BFRI stock opened at $1.16 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.08 and a current ratio of 1.18. Biofrontera has a fifty-two week low of $0.55 and a fifty-two week high of $1.66. The firm has a market cap of $17.23 million, a P/E ratio of -2.58 and a beta of 0.83. The business’s 50 day moving average price is $1.31 and its 200-day moving average price is $1.09.

Biofrontera (NASDAQ:BFRI – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%.The company had revenue of $12.00 million during the quarter, compared to the consensus estimate of $9.50 million. On average, equities research analysts anticipate that Biofrontera will post -0.6 earnings per share for the current year.

Biofrontera Company Profile

(Get Free Report)

Biofrontera Inc (NASDAQ:BFRI) is a commercial-stage biopharmaceutical company focused on dermatology. The company develops and markets prescription therapies for the treatment of skin conditions, with an emphasis on products that address actinic keratosis and other dermatologic diseases.

Its principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, which is used in combination with the BF-RhodoLED lamp in photodynamic therapy for actinic keratoses. Biofrontera also provides the BF-RhodoLED photodynamic therapy lamp system used by healthcare professionals to activate the treatment.

Biofrontera Inc is based in the United States and operates as part of the broader Biofrontera corporate group, which has German roots and an international dermatology business.

Read More

• Five stocks we like better than Biofrontera
• Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
• Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
• AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
• Insiders Signal Deep Value In DICK’s Sporting Goods

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.